Larimar Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Larimar Therapeutics generated cash of -$33,459,000, which is less than the previous year. Cash used in financing activities reached the amount of $30,000 last year. Net change in cash is therefore -$76,000.
Cash Flow
| 2014 | -28.24M | -57.31M | 108.14M |
|---|---|---|---|
| 2015 | -59.55M | -92.11M | 129.16M |
| 2016 | -51.97M | 51.44M | -2.71M |
| 2017 | -43.78M | 35.64M | 16.56M |
| 2018 | -51.48M | -6.86M | 66.90M |
| 2019 | -22.69M | -83K | 19.39M |
| 2020 | -42.19M | 17.09M | 93.58M |
| 2021 | -42.10M | 24.16M | 19.88M |
| 2022 | -27.56M | -90.96M | 75.25M |
| 2023 | -33.45M | 33.35M | 30K |
LRMR Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 26.82M | 71.43M | 69.48M | 1.00M | 4.39M | 40.77M | 32.35M | 35.59M | 58.10M | 35.51M |
Operating activities | ||||||||||
Net income | -36.94M | -35.35M | -50.63M | -42.48M | -23.13M | -61.36M | -52.02M | -57.87M | -74.28M | -36.47M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 311K | 318K | 326K | 155K | 78K | 261K | 188K | 212K | 70K | 16K |
Stock-based compensation expense | 7.61M | 6.61M | 5.47M | 2.16M | 129K | 0 | 0 | 0 | 8.58M | 0 |
| Deferred income tax benefit | 7.61M | 6.61M | 5.47M | 2.16M | 129K | 0 | 0 | 0 | 8.58M | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 1.28M | -666K | -553K | 970K | -1.01M | 0 |
Inventories | 0 | 0 | 0 | 0 | -1.28M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -403K | 26K | -974K | -3.28M | 2.63M | 432K | -448K | 4.92M | 4.91M | 815K |
Cash generated by operating activities | -33.45M | -27.56M | -42.10M | -42.19M | -22.69M | -51.48M | -43.78M | -51.97M | -59.55M | -28.24M |
Investing activities | ||||||||||
Purchases Of Investments | -101.23M | -133.61M | -8.24M | -24.48M | -82.86M | -117.14M | -114.51M | -136.52M | -287.49M | -57.2M |
Investments In Property Plant And Equipment | -164K | -100K | -333K | -62K | -83K | -108K | -55K | -660K | -595K | -58K |
Acquisitions Net | -33.51K | 90.86K | -24.50K | -1.29M | -26.02M | 6.75M | 0 | 0 | 91.50M | 0 |
Cash generated by investing activities | 33.35M | -90.96M | 24.16M | 17.09M | -83K | -6.86M | 35.64M | 51.44M | -92.11M | -57.31M |
Financing activities | ||||||||||
Common Stock Issued | 30K | 75.25M | 19.88M | 75.59M | 19.39M | 66.90M | 195K | 220K | 130.54M | 3.56M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 67.22M | 195K | 220K | 131.01M | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 16.36M | -2.93M | -1.38M | 0 |
Cash used in financing activities | 30K | 75.25M | 19.88M | 93.58M | 19.39M | 66.90M | 16.56M | -2.71M | 129.16M | 108.14M |
Net Change In Cash | -76K | -43.27M | 1.94M | 68.47M | -3.38M | 8.55M | 8.42M | -3.24M | -22.50M | 22.58M |
Cash at end of period | 26.74M | 28.16M | 71.43M | 69.48M | 1.00M | 49.33M | 40.77M | 32.35M | 35.59M | 58.10M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |